

## Identification of Factors Related to Sexual Dysfunction in Type 2 Diabetic Women

Zeinab Entezari<sup>1</sup>, Nastaran Injinari<sup>1</sup>, Mahmoud Vakili<sup>2</sup>, Nasim Namiranian<sup>1\*</sup>

<sup>1</sup>Diabetes Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.

<sup>2</sup>Department of Community and Preventive Medicine, Health Monitoring Research Center, School of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.

### Abstract

**Objective:** Type 2 diabetes mellitus (T2DM) is one of the most common metabolic diseases among women. Sexual dysfunction (SD) is a complication in patients with T2DM that has received less attention among women than men. This study aimed to assess the factors related to female SD in T2DM patients.

**Materials and Methods:** 120 women with T2DM who referred to the Yazd Diabetes Center in 2019-2020 were selected. Female sexual function index (FSFI) as a valid questionnaire was used. Neuropathy, nephropathy, retinopathy, hyperlipidemia, hypertension, diabetes medication, Hb1Ac, age, and duration of diabetes as factors related to SD were assessed. The T-test and chi-square tests were used to analyze the data by SPSS 22 software.

**Results:** The mean age of participants was 48.40 ( $\pm 7.35$ ). The SD was impaired in 85.8% of subjects and none of the participants showed a level of good function in any of the sexual domains. There was a significant relationship between SD and neuropathy ( $P = 0.005$ ), hyperlipidemia ( $P = 0.007$ ), hypertension ( $P = 0.015$ ), diabetes medication ( $P = 0.005$ ), age ( $P = 0.0001$ ), and duration of diabetes ( $P = 0.0001$ ). There was no significant relationship between SD and retinopathy ( $P = 0.565$ ), nephropathy ( $P = 0.288$ ), and Hb1Ac ( $P = 0.92$ ).

**Conclusion:** The frequency of SD in females with T2DM remarkably was high and the factors including age, duration of diabetes, diabetes medication, hypertension, hyperlipidemia, and neuropathy were identified as factors related to SD.

**Keywords:** Type 2 diabetes mellitus, Women, Sexual dysfunction

### QR Code:



**Citation:** Entezari Z, Injinari N, Vakili M, Namiranian N. Identification of Factors Related to Sexual Dysfunction in Type 2 Diabetic Women. IJD0 2023; 15 (2) :66-72

**URL:** <http://ijdo.ssu.ac.ir/article-1-788-en.html>



10.18502/ijdo.v15i2.12963

### Article info:

**Received:** 08 January 2023

**Accepted:** 08 April 2023

**Published in June 2023**



This is an open access article under the (CC BY 4.0)

### Corresponding Author:

**Nasim Namiranian**, Associate Professor, Diabetes Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.

**Tel:** (98) 353 728 0215

**Email:** [namiranian.nasim@gmail.com](mailto:namiranian.nasim@gmail.com)

**Orcid ID:** 0000-0002-5133-6204

## Introduction

Type 2 diabetes mellitus (T2DM) is the most common metabolic disease and a public health problem that leads to complications and reduced quality of life (1-3). T2DM is one of the most important causes of chronic renal failure worldwide (4). It has been estimated 9.3% of people had diabetes in 2019 and it will rise to 10.9% in 2045 (5). Yazd is one of the fifth provinces in Iran in the ranking of diabetes prevalence. T2DM prevalence is 14.5% in adults of Yazd (6).

Microvascular complications such as retinopathy, nephropathy, and neuropathy as well as macrovascular complications such as peripheral artery disease, coronary artery disease, and stroke are common complications of diabetes (4,7). Besides, there is a wide range of complications such as xerostomia, candidiasis, and periodontitis in patients with T2DM than in healthy subjects (8). Depression is one of the miscellaneous complications of diabetes and it has been estimated that women with diabetes are at a higher risk for depressive symptoms (9,10). On the other hand, sexual dysfunction (SD) prevalence in T2DM women is high (11). Important factors including cardiovascular, reproductive hormones, and neurons influence sexual health (12). Based on FSFI, sexual function is defined as dyspareunia, satisfaction, arousal, lubrication, orgasm, and desire (13).

In a study in Iran, findings from 100 men and 100 women with diabetes showed the prevalence of SD is high in both genders (14). Another study by Ezeani et al. in southeast Nigeria revealed SD is very common in women with T2DM and age, body mass index (BMI), and fasting blood sugar (FBS) are predictors for SD in these patients (15). A systematic review and meta-analysis in 2019 revealed that in recent years, the rate of sexual disorders in women with T2DM significantly has increased. Moreover, this study reported the highest and lowest outbreak of SD in women with T2DM were in Iran and Italy

respectively (16). In addition to female sexual disorder, diabetes influences male sexual disorder especially erectile dysfunction (17). Satisfaction with marital life and sexual function is of particular importance but has received less attention in medical studies and interventions. It is argued cultural taboos and misconceptions about women's sexual activity have led to women usually not expressing their sexual problems (12,16).

Although sexual satisfaction and its related factors have been studied in healthy people and various patients, but it is still questionable. Evaluation of sexual satisfaction in patients with diabetes due to its impact on quality of life has many values. This study aimed to assess the frequency of SD in women with T2DM and finding the most important related factors to female sexual dysfunction in these patients.

## Materials and Methods

In this analytical cross-sectional study, we enrolled 120 women with T2DM who referred to the Yazd Diabetes Center in 2019-2020. The systematic random sampling method was done. The aims of the research and the study steps were explained by female general practitioners. The inclusion criteria for the group of participants were: T2DM diagnosis at least during the past two years, age 35-60 years, married and cohabitation, no alcohol addiction, and satisfaction with participation in the study. The following patients were excluded from the study: having neurological diseases, history of performing surgeries on genitals, the existence of severe physical disabilities or disabilities of oneself or partner, consumption of known drugs that affect sexual function (increasing or decreasing), and the existence of known chronic diseases affecting sexual function such as cardiovascular disease and cancer, pregnancy, breastfeeding, menopause, and the existence of another sexual partner for husband. The data collection

method using a valid questionnaire with a specified validity and reliability was obtained. The questionnaire was provided in two parts. The first part of the questionnaire was a checklist of patient's profile such as age, marital status, employment status, education status, diabetes complications, HbA1c level, hyperlipidemia, hypertension, drug addiction, and duration of diabetes. Blood pressure > 80/135 as hypertension and triglycerides > 250 as hyperlipidemia were regarded.

In the second part of the questionnaire, FSFI as a self-report instrument was assessed in 19 items within six domains: dyspareunia, satisfaction, arousal, lubrication, orgasm, and desire (13). The total score was regarded from 15 to 75 and based on the sexual function the patients were categorized into dysfunction (15-25), moderate function (25-50), and good function (>50). The Kolmogorov-Smirnov test was used to assess the normality of distribution. The chi-square test was used for qualitative variables and the T-test was used for quantitative data. All statistical analysis was performed using SPSS, version 22 software, and *P* less than 0.05 (*P* < 0.05) was considered significant.

### Ethical considerations

This manuscript has been based on a thesis (Thesis code: 5904) and approved by the ethics committee of Shahid Sadoughi University of Medical Sciences, Yazd, Iran (IR.SSU.MEDICINE.REC. 1398.021).

### Results

In this study, 120 women with T2DM and married according to the inclusion criteria were included. Information on demographics and clinical features is given in Table 1. The mean age of participants was 48.40 ( $\pm 7.35$ ) and the mean HbA1c value was 7.66 ( $\pm 1.04$ ). Occupationally, most patients were unemployed (78.3%). Moreover, 55% of patients had neuropathy, 41.7% retinopathy, 15% nephropathy, 41.7% hyperlipidemia, and 38.3% hypertension. Also, none of the patients had a drug addiction. As shown in Table 2, based on the total FSFI score, none of the subjects were in a good function, and 85.8 percentage subjects were in a state of SD. The correlation of studied variables with six sexual domains to the etiology of SD in women with T2DM is shown in Tables 3-5. There was a significant relationship between the total FSFI score and neuropathy (*P* = 0.005), hyperlipidemia (*P* = 0.007), hypertension (*P* = 0.015), type of treatment (*P* = 0.005), age (*P* = 0.0001), and duration of diabetes (*P* = 0.0001). On the contrary, there was no significant relationship between the total FSFI score and retinopathy, nephropathy, and Hb1Ac (*P* > 0.05).

### Discussion

In the cross-sectional study, we evaluated female SD based on FSFI in 120 women with T2DM. The frequency of sexual dysfunction and moderate function was 85.8% and 14.2% respectively. None of the participants showed

**Table 1. Demographic and clinical characteristics of the participants**

| Variables          | Frequency (%)          |
|--------------------|------------------------|
| Employment Status  | Government employee    |
|                    | 2 (1.7%)               |
|                    | Private employee       |
|                    | 12 (10%)               |
|                    | unemployed             |
|                    | 94 (78.3%)             |
| Education          | Retired                |
|                    | 12 (10%)               |
|                    | Relatively appropriate |
|                    | 70 (58.3%)             |
|                    | Quite appropriate      |
|                    | 18 (15%)               |
|                    | Illiterate             |
|                    | 20 (16.7%)             |
|                    | Primary                |
|                    | 20 (16.7%)             |
| Diabetes treatment | Middle school          |
|                    | 20 (16.7%)             |
|                    | High school            |
|                    | 16 (13.3%)             |
|                    | Diploma                |
|                    | 30 (25%)               |
|                    | Bachelor and higher    |
|                    | 4 (3.3%)               |
|                    | Non-insulin            |
|                    | 86 (71.7%)             |
|                    | Insulin                |
|                    | 34 (28.3%)             |

**Table 2. Female sexual function index in patients**

| Domain                  | Sexual function   | Frequency (%) |
|-------------------------|-------------------|---------------|
| Overall sexual function | Dysfunction       | 103 (85.8%)   |
|                         | Moderate function | 17 (14.2%)    |
|                         | Good function     | -             |
| Sexual desire           | Dysfunction       | 48 (40%)      |
|                         | Moderate function | 72 (60%)      |
|                         | Good function     | -             |
| Dyspareunia             | Dysfunction       | 75 (62.5%)    |
|                         | Moderate function | 45 (37.5%)    |
|                         | Good function     | -             |
| Sexual satisfaction     | Dysfunction       | 89 (74.2%)    |
|                         | Moderate function | 31 (25.8%)    |
|                         | Good function     | -             |
| Arousal                 | Dysfunction       | 78 (65%)      |
|                         | Moderate function | 42 (35%)      |
|                         | Good function     | -             |
| Lubrication             | Dysfunction       | 75 (62.5%)    |
|                         | Moderate function | 45 (37.5%)    |
|                         | Good function     | -             |
| Orgasm                  | Dysfunction       | 73 (60.8%)    |
|                         | Moderate function | 47 (39.2%)    |
|                         | Good function     | -             |

**Table 3. Association between diabetes complications and sexual domains**

| Sexual domains      | Sexual function   | Neuropathy | P       | Retinopathy | P      | Nephropathy | P     |
|---------------------|-------------------|------------|---------|-------------|--------|-------------|-------|
| Total score         | Dysfunction       | 62 (51.7%) | 0.005*  | 44 (36.6%)  | 0.565  | 14 (11.7%)  | 0.288 |
|                     | Moderate function | 4 (3.3%)   |         | 6 (5%)      |        | 4 (3.3%)    |       |
| Dyspareunia         | Dysfunction       | 49 (40.8%) | 0.003*  | 31 (25.8%)  | 0.924  | 12 (10%)    | 0.692 |
|                     | Moderate function | 17 (14.2%) |         | 19 (15.8%)  |        | 6 (5%)      |       |
| Sexual satisfaction | Dysfunction       | 56 (46.7%) | 0.003*  | 38 (31.7%)  | 0.698  | 14 (11.7%)  | 0.704 |
|                     | Moderate function | 10 (8.3%)  |         | 12 (10%)    |        | 4 (3.3%)    |       |
| Arousal             | Dysfunction       | 55 (45.8%) | 0.0001* | 39 (32.5%)  | 0.012* | 13 (10.8%)  | 0.486 |
|                     | Moderate function | 11 (9.2%)  |         | 11 (9.2%)   |        | 5 (4.2%)    |       |
| Lubrication         | Dysfunction       | 50 (41.7%) | 0.001*  | 36 (30%)    | 0.069  | 11 (9.2%)   | 0.895 |
|                     | Moderate function | 16 (13.3%) |         | 14 (11.7%)  |        | 7 (5.8%)    |       |
| Orgasm              | Dysfunction       | 49 (40.8%) | 0.001*  | 37 (30.8%)  | 0.013* | 13 (10.8%)  | 0.283 |
|                     | Moderate function | 17 (14.2%) |         | 13 (10.8%)  |        | 5 (4.2%)    |       |
| Sexual desire       | Dysfunction       | 54 (45%)   | 0.0001* | 36 (30%)    | 0.023* | 11 (9.2%)   | 0.917 |
|                     | Moderate function | 12 (10%)   |         | 14 (11.7%)  |        | 7 (5.8%)    |       |

The chi-square test was used to analyze the data.\* Significant

**Table 4. Association between hyperlipidemia, hypertension, and insulin with sexual domains**

| Sexual domains      | Sexual function   | Hyperlipidemia | P       | Hypertension | P       | Insulin treatment | P       |
|---------------------|-------------------|----------------|---------|--------------|---------|-------------------|---------|
| Total score         | Dysfunction       | 48 (40%)       | 0.007*  | 44 (36.7%)   | 0.015*  | 34 (28.3%)        | 0.005*  |
|                     | Moderate function | 2 (1.7%)       |         | 2 (1.7%)     |         | -                 |         |
| Dyspareunia         | Dysfunction       | 38 (31.7%)     | 0.01*   | 36 (30%)     | 0.005*  | 23 (19.2%)        | 0.46    |
|                     | Moderate function | 12 (10%)       |         | 10 (8.3%)    |         | 11 (9.2%)         |         |
| Sexual satisfaction | Dysfunction       | 46 (38.3%)     | 0.0001* | 42 (35%)     | 0.001*  | 30 (25%)          | 0.027*  |
|                     | Moderate function | 4 (3.3%)       |         | 4 (3.3%)     |         | 4 (3.3%)          |         |
| Arousal             | Dysfunction       | 39 (32.5%)     | 0.012*  | 36 (30%)     | 0.016*  | 30 (25%)          | 0.001*  |
|                     | Moderate function | 11 (9.2%)      |         | 10 (8.3%)    |         | 4 (3.3%)          |         |
| Lubrication         | Dysfunction       | 41 (34.2%)     | 0.0001* | 38 (31.7%)   | 0.0001* | 29 (24.2%)        | 0.001*  |
|                     | Moderate function | 9 (7.5%)       |         | 8 (6.7%)     |         | 5 (4.2%)          |         |
| Orgasm              | Dysfunction       | 39 (32.5%)     | 0.001*  | 36 (30%)     | 0.002*  | 28 (23.3%)        | 0.002*  |
|                     | Moderate function | 11 (9.2%)      |         | 10 (8.3%)    |         | 6 (5%)            |         |
| Sexual desire       | Dysfunction       | 39 (32.5%)     | 0.001*  | 38 (31.7%)   | 0.0001* | 30 (25%)          | 0.0001* |
|                     | Moderate function | 11 (9.2%)      |         | 8 (6.7%)     |         | 4 (3.3%)          |         |

The chi-square test was used to analyze the data.\* Significant

a level of good function.

Among sexual domains, the frequency of dysfunction was high than moderate function except in the sexual desire domain which 60%

Table 5. Relationship between sexual function and HbA1c, age, and duration of diabetes

| Sexual domains      | Sexual function   | HbA1c<br>Mean (± SD) | P     | Age<br>Mean (± SD) | P       | Duration of diabetes<br>Mean (± SD) | P       |
|---------------------|-------------------|----------------------|-------|--------------------|---------|-------------------------------------|---------|
| Total score         | Dysfunction       | 7.66 (±1.01)         | 0.92  | 49.89 (±6.70)      | 0.0001* | 8.27 (±3.83)                        | 0.0001* |
|                     | Moderate function | 7.64 (±1.29)         |       | 39.41 (±3.89)      |         | 4.06 (±0.89)                        |         |
| Dyspareunia         | Dysfunction       | 7.61 (±1.004)        | 0.53  | 51.62 (±5.20)      | 0.0001* | 8.93 (±3.93)                        | 0.0001* |
|                     | Moderate function | 7.74 (±1.12)         |       | 43.04 (±7.20)      |         | 5.58 (±2.65)                        |         |
| Sexual satisfaction | Dysfunction       | 7.64 (±1.002)        | 0.705 | 51.04 (±5.60)      | 0.0001* | 8.76 (±3.85)                        | 0.0001* |
|                     | Moderate function | 7.72 (±1.18)         |       | 40.83 (±6.40)      |         | 4.55 (±1.38)                        |         |
| Arousal             | Dysfunction       | 7.58 (±0.91)         | 0.26  | 51 (±6.45)         | 0.0001* | 8.92 (±4.05)                        | 0.0001* |
|                     | Moderate function | 7.80 (±1.26)         |       | 43.59 (±6.49)      |         | 5.36 (±1.94)                        |         |
| Lubrication         | Dysfunction       | 7.62 (±1.02)         | 0.60  | 52.04 (±5.11)      | 0.0001* | 9.21 (±3.98)                        | 0.0001* |
|                     | Moderate function | 7.72 (±1.09)         |       | 42.35 (±6.49)      |         | 5.11 (±1.66)                        |         |
| Orgasm              | Dysfunction       | 7.65 (±1.02)         | 0.86  | 51.82 (±5.38)      | 0.0001* | 9.41 (±3.88)                        | 0.0001* |
|                     | Moderate function | 7.68 (±1.10)         |       | 43.10 (±6.86)      |         | 4.98 (±1.62)                        |         |
| Sexual desire       | Dysfunction       | 7.61 (±0.94)         | 0.54  | 52.09 (±5.60)      | 0.0001* | 9.25 (±4.04)                        | 0.0001* |
|                     | Moderate function | 7.73 (±1.19)         |       | 42.87 (±6.10)      |         | 5.31 (±1.84)                        |         |

SD: Standard deviation; HbA1c: glycated hemoglobin,. The T-test was used to analyze the data., \* Significant

of subjects had a moderate function. A study in Zarand, Kerman, Iran that was conducted on 120 diabetic women, indicated SD in dyspareunia, satisfaction, arousal, lubrication, and orgasm domains were lower in patients compared to healthy women; but in the sexual desire domain, differences were not significant between the diabetic group and the control group (18). A study conducted in southeast Nigeria reported that based on the FSFI score, only desire, lubrication, and orgasm domains significantly were fewer in women with T2DM compared to healthy individuals (15).

Nitric oxide is an invisible molecule that plays a key role in a wide range of physiological processes in the body, including vasodilation, a neurotransmitter in the brain, regulation of gonadotropin hormones and sexual behavior, erection, and ejaculation (19). It is argued that in people with T2DM, the level of nitric oxide decreases in the body and leads to reduced libido, lubrication, arousal, and orgasm in women with T2DM (16,20). Besides, diabetic depression indirectly affects the sexual desire of women with diabetes (21). Therefore, it is suggested the level of nitric oxide and depression be measured in diabetic patients in future studies. Given that SD is related to the patient's mental health and fertility, it should be recognized as an important issue among physicians in follow-up sessions.

Comparing diabetic patients and the presence or absence of symptoms of

neuropathy, retinopathy, and nephropathy, it was found that there was a significant relationship between all sexual domains and neuropathy, and patients with neuropathy symptoms obtained a lower score compared to patients with no neuropathy symptom. Moreover, patients with retinopathy remarkably have a lower score in arousal, orgasm, and sexual desire, but based on a total score, there was no significant correlation between retinopathy and SD. Also, there was no significant association between SD and nephropathy. Contrary to our study, a study by Yenice et al. on 149 diabetic women showed diabetic women who more suffer from retinopathy as well as nephropathy significantly had SD (22). This may be due to differences in sociodemographics between our studied group and Yenice's study.

There is strong evidence that hypertension, as well as hyperlipidemia, negatively influence SD (23,24). Our study was consistent with these studies and a significant relationship was observed between hypertension and hyperlipidemia with SD in the participants. A study by Elyasi et al. on one hundred and fifty women with T2DM reported depression and SD are common in participants and parameters such as hypertension, HbA1c, and duration of diabetes with SD had no significant relationship (25). In this study, age and duration of diabetes were related factors to SD, but HbA1c were not associated with SD. Y1 ldi z et al. indicated SD is high in Turkish



women with T2DM, and SD increases with age and menopause (26). According to a study on diabetic women, concentrations of HbA1c, triglycerides, glucose, and insulin were remarkably higher in diabetic women with SD compared to diabetic women without SD (22).

Tuncel et al. reported there is an association between insulin therapy and female sexual dysfunction (27). It is argued that the insulin hormone can regulate the activities of the steroidogenesis enzyme. On the other hand, insulin can increase the proliferation of vaginal epithelium (28). The results of our study showed in diabetic women, SD in subjects with oral treatment significantly was high compared with insulin treatment.

## Conclusions

Based on the total score of FSFI, we demonstrated 85.8% of women with T2DM had SD, and the factors including age, duration of diabetes, type of treatment, hypertension, hyperlipidemia, and neuropathy were identified as related factors to SD. This study was established as a background for

interventional and therapeutic actions. As a consequence, it is recommended that similar descriptive and longitudinal studies with a larger population be performed in future research to better manage the disease by identifying important factors in sexual disorders and intervening with these factors.

## Acknowledgments

The authors would like to thank Shahid Sadoughi University of Medical Sciences, Yazd, Iran, for their support of this study. They are also grateful to the staff from the Diabetes Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran, for to cooperate with us.

## Funding

This research received no specific grant from any funding agency.

## Conflict of Interest

The authors declare no conflict of interest.

## References

1. Chaudhury A, Duvoor C, Reddy Dendi VS, Kraleti S, Chada A, Ravilla R, et al. Clinical review of antidiabetic drugs: implications for type 2 diabetes mellitus management. *Frontiers in endocrinology*. 2017;8:6.
2. Mehrabbeik A, Namiranian N, Azizi R, Meybody MA, Shariati M, Kohani HA. Investigation of Association Between Insulin Injection Technique and Blood Glucose Control in Patients with Type 2 Diabetes. *International Journal of Endocrinology and Metabolism*. 2022;20(4):1–7.
3. Firouzkouhi M, Abdollahimohammad A. Lived Experiences of Type 2 Diabetes with Irreversible Complications: A Qualitative Research. *Iranian journal of diabetes and obesity*. 2022;14(3):29–35.
4. Papatheodorou K, Banach M, Bekiari E, Rizzo M, Edmonds M. Complications of diabetes 2017. *Journal of diabetes research*. 2018;2018.
5. Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas. *Diabetes research and clinical practice*. 2019;157:107843.
6. Mirzaei M, Rahmanian M, Mirzaei M, Nadjarzadeh A, Dehghani Tafti AA. Epidemiology of diabetes mellitus, pre-diabetes, undiagnosed and uncontrolled diabetes in Central Iran: results from Yazd health study. *BMC public health*. 2020;20:1–9.
7. Samimagham HR, Farshidi H, Nikparvar M, Arabi M, Tamaddondar M, Ghasemzadeh M, et al. The association of glomerular filtration rate with coronary artery disease in type 2 diabetic patients. *Iranian Journal of Diabetes and Obesity*. 2020;12(3):126–31.
8. Ghadiri-Anar A, Kheirollahi K, Hazar N, Namiranian N, Akhondi-Meybody M, Mayani MA. Frequency of Oral Manifestation in Diabetic Patients in Yazd 2016–2017. *Iranian journal of diabetes and obesity*. 2020 ;12(2):63–8.
9. Andreoulakis E, Hyphantis T, Kandylis D, Iacovides A. Depression in diabetes mellitus: a comprehensive review. *Hippokratia*. 2012 Jul;16(3):205–14.

10. Holt RI, Groot M de, Golden SH. Diabetes and depression. *Curr Diab Rep*. 2014;14(6):491.
11. Ozcan S, Sahin NH, Bilgic D, Yilmaz SD. Is sexual dysfunction associated with diabetes control and related factors in women with diabetes?. *Sexuality and Disability*. 2011;29:251-61.
12. Flynn KE, Lin L, Bruner DW, Cyranowski JM, Hahn EA, Jeffery DD, et al. Sexual satisfaction and the importance of sexual health to quality of life throughout the life course of US adults. *The journal of sexual medicine*. 2016;13(11):1642-50.
13. Rosen, C. Brown, J. Heiman, S. Leiblum, C. Meston, R. Shabsigh, D. et al. D'Agostino R. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. *Journal of sex & marital therapy*. 2000;26(2):191-205.
14. Ziaei-Rad M, Vahdaninia M, Montazeri A. Sexual dysfunctions in patients with diabetes: a study from Iran. *Reproductive Biology and Endocrinology*. 2010;8:1-8.
15. Ezeani I, Onyeonoro U, Ugwu E. Evaluation of female sexual function in persons with type 2 diabetes mellitus seen in a tertiary hospital in Southeast Nigeria with emphasis on its frequency and predictors. *Journal of sex & marital therapy*. 2020;46(2):170-6.
16. Rahmanian E, Salari N, Mohammadi M, Jalali R. Evaluation of sexual dysfunction and female sexual dysfunction indicators in women with type 2 diabetes: a systematic review and meta-analysis. *Diabetology & metabolic syndrome*. 2019;11:1-7.
17. Bahar A, Elyasi F, Moosazadeh M, Afradi G, Kashi Z. Sexual dysfunction in men with type II diabetes. *Casp J Intern Med [Internet]*. 2020 [cited 2020 Nov 10];11(3):295–303. Available from: [/pmc/articles/PMC7442469/?report=abstract](https://pmc/articles/PMC7442469/?report=abstract)
18. Alikamali M, Khodabandeh S, Motesaddi M. Sexual dysfunction in males and females with type 2 diabetes referring to healthcare centers of Zarand, Kerman: a cross-sectional study. *Shiraz E-Medical Journal*. 2019;20(8).
19. Kumar S, Singh RK, Bhardwaj TR. Therapeutic role of nitric oxide as emerging molecule. *Biomedicine & Pharmacotherapy*. 2017;85:182-201.
20. Abdaly MS, Azizi MS, Wijaya IP, Nugroho P, Purnamasari D. Subclinical Atherosclerosis in Young Adult Population with First Degree Relatives of Type 2 Diabetes Mellitus. *Acta Med Indones*. 2019;51(2):169-76.
21. Gandhi J, Dagur G, Warren K. Effect of diabetes mellitus on sexual arousal and intercourse. *Transl Biomed*. 2016;7(2):2-5.
22. Y Yenice MG, Danacı oğ lu YO, Mert M, Karakaya P, Seker KG, Akkaş F, et al. Evaluation of factors affecting sexual dysfunction in female patients with diabetes mellitus. *Archives of Endocrinology and Metabolism*. 2020;64:319-25.
23. Schulster ML, Liang SE, Najari BB. Metabolic syndrome and sexual dysfunction. *Current Opinion in Urology*. 2017;27(5):435-40.
24. Xu Y, Zhang Y, Yang Y, Liu L, Chen Y, Liu X. Prevalence and correlates of erectile dysfunction in type 2 diabetic men: a population-based cross-sectional study in Chinese men. *International journal of impotence research*. 2019;31(1):9-14.
25. Elyasi F, Kashi Z, Tasfieh B, Bahar A, Khademloo M. Sexual dysfunction in women with type 2 diabetes mellitus. *Iranian journal of medical sciences*. 2015 ;40(3):206-13.
26. Oztürk M, Yildiz S, Gonen MS. Sexual Function Disorders in Type 2 Diabetic Women; Cross-Sectional Study. *Eastern Journal of Medicine*. 2020;25(4):552-7.
27. Tuncel E, Durgun O, Peynirci H, Ersoy C. Sexual dysfunction in female patients with type 2 diabetes mellitus: a cross-sectional single-centre study among Turkish patients. *Human fertility*. 2017;20(3):192-9.
28. Barbagallo F, Mongioi LM, Cannarella R, La Vignera S, Condorelli RA, Calogero AE. Sexual dysfunction in diabetic women: an update on current knowledge. *Diabetology*. 2020;1(1):11-21.